NCT01326533

Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes

Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: University of Pittsburgh · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology to study changes in insulin secretion and glucose tolerance in subjects at risk for developing Type 2 diabetes.

Detailed description

Diabetes is approaching epidemic proportions in the United States. This study evaluates the mechanisms of action of a generic drug that may have effects on glucose metabolism.

Conditions

• Pre-diabetes

Interventions

Type	Name	Description
DRUG	hydroxychloroquine	Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
OTHER	Placebo	Thirteen weeks of oral placebo provided as capsules

Timeline

• Start date: 2011-03-01
• Primary completion: 2013-03-01
• Completion: 2014-12-01
• First posted: 2011-03-31
• Last updated: 2016-02-26
• Results posted: 2016-01-29

Locations

1 site across 1 country: United States